Issue Price
₹807
Per Share
GMP
+₹132
+16.36% Grey Market
Est. Listing
₹939
Expected Price
Min. Application
₹29,052
2 lots × 18 shares
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities.The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics.As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.StrengthsProprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.Strong R&D capabilities supported by an extensive global patent portfolio.Scalable business model with recurring revenues from diagnostic test kits.Global presence across 90+ countries with strong government and institutional customer base.Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Molbio Diagnostics Ltd proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| QIB (Ex Anchor) | 5,812,862 | — | ₹469.10 Cr | 75.13x |
| NII / HNI | 1,743,860 | — | ₹140.73 Cr | 49.62x |
| Retail (RII) | 4,069,005 | — | ₹328.37 Cr | 12.65x |
| TOTAL | 20,519 | 100.00% | ₹1.66 Cr | 1.95x |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹188,838 |
| sNII (Min) | 14 | 252 | ₹203,364 |
| bNII (Min) | 69 | 1,242 | ₹1,002,294 |
| Particulars | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue from Operations | 1455.17 | 1027.94 | 840.66 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| Profit After Tax (PAT) | 164.14 | 138.58 | 83.54 |
| Net Worth | 1144.68 | 952.95 | 807.94 |
| Total Assets | 2148.42 | 1461.56 | 1221.06 |
| Reserves & Surplus | 1148.84 | 990.84 | 845.48 |
| Total Borrowings | 412.64 | 123.16 | 174.58 |